Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022005678 - DUAL CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CCD99- AND CLEC12A-EXPRESSING CANCERS

Publication Number WO/2022/005678
Publication Date 06.01.2022
International Application No. PCT/US2021/035375
International Filing Date 02.06.2021
IPC
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C12N 5/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Applicants
  • H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. [US]/[US]
Inventors
  • DAVILA, Marco L.
Agents
  • GILES, P. Brian
Priority Data
63/047,57302.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) DUAL CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CCD99- AND CLEC12A-EXPRESSING CANCERS
(FR) LYMPHOCYTES T DE RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE DOUBLE CIBLANT CD99 ET CANCERS EXPRIMANT CLEC12A
Abstract
(EN) Disclosed herein are compositions and methods for targeted treatment of cancers co-expressing CD99 and CLEC12A. In particular, disclosed herein are immune effector cells genetically modified to express at least two chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target cancers co-expressing CD99 and CLEC12A.
(FR) L'invention concerne des compositions et des méthodes pour le traitement ciblé de cancers co-exprimant CD99 et CLEC12A. En particulier, l'invention concerne des cellules effectrices immunes génétiquement modifiées pour exprimer au moins deux polypeptides de récepteurs antigéniques chimériques (CAR) qui peuvent être utilisés avec un transfert cellulaire adoptif pour cibler des cancers co-exprimant CD99 et CLEC12A.
Latest bibliographic data on file with the International Bureau